Satoru Kitazono

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.

Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 30, 2026

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 05, 2025

Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC.

Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC.

Journal: Cancer science

Published: July 17, 2025

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 09, 2024

Effect of Perioperative Inhaled Tiotropium for patients with chronic Obstructive Pulmonary disease in Esophageal cancer surgery (EPITOPE): an open-label, randomized, parallel-group pilot study.

Effect of Perioperative Inhaled Tiotropium for patients with chronic Obstructive Pulmonary disease in Esophageal cancer surgery (EPITOPE): an open-label, randomized, parallel-group pilot study.

Journal: General thoracic and cardiovascular surgery

Published: July 21, 2024

High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group).

High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group).

Journal: Japanese journal of clinical oncology

Published: April 17, 2024

Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.

Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.

Journal: Thoracic cancer

Published: December 07, 2023

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.

Journal: The New England journal of medicine

Published: October 23, 2023

Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.

Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.

Journal: Thoracic cancer

Published: September 30, 2023

First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

Journal: Japanese journal of clinical oncology

Published: September 25, 2023

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy.

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy.

Journal: Thoracic cancer

Published: July 25, 2023

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 16, 2023

Showing 1-12 of 72

Last Updated: 09/26/2026